Celldex Therapeutics, Inc. (NASDAQ:CLDX) gains that it recorded a week ago in response to its update of positive data from a Phase II clinical study evaluating antibody medication conjugate glembatumumab vedotin, has been washed away. The results were showcased at the European Society for Medical Oncology event in Copenhagen. Despite this report, the stock failed to retain its gains.

Did you know that this HEALTH CARE Stock is about to Storm Wall Street ? Click to Read More 

As per the report, the objective response rate was 11% (n=7/62) while the median response duration was 6 months (heavily pretreated population). In addition, the disease control rate was 52% as was the proportion of subjects experiencing tumor shrinkage. Median PFS came at 4.4 months. Celldex has amended the study protocol to add a second cohort of subjects who will be cured with a combination of varlilumab and glembatumumab vedotin. After enrollment is closed, a new arm will be discovered evaluating a combination of an immune checkpoint inhibitor and glembatumumab vedotin.

The management view

Patrick Ott, M.D., Ph.D., an investigator in the trial said that while BRAF targeted therapy and immune checkpoint inhibitors have considerably changed results for many subjects with metastatic melanoma, people who either do not progress or respond through these treatments have very limited treatment alternatives. The single-agent activity seen in this trial and the related duration of response is extremely promising. He expects that pursuing combination trials of glembatumumab vedotin, along with checkpoint inhibition, could drive in benefit to melanoma and cancer patients.

Thomas Davis, M.D., the Chief Medical Officer of Celldex, said that it is evident depending on these study data that refractory metastatic melanoma acts as responsive target sign for glembatumumab vedotin. gpNMB is highly stated in melanoma with tissue samples on trial testing positive, and nearly 80% of tumors showing 100% expression in epithelial cells. The team is motivated by the data they have recorded to date in this progressive, checkpoint refractory set up. Also, they consider leveraging the immune system via combination therapy is an important next step for subjects in in this indication.

This trial was a Phase II, open-label trial of glembatumumab vedotin in subjects with unresectable stage III or stage IV melanoma. The median count of prior therapies was 3. All subjects had advanced after checkpoint therapy, and nearly all patients received both ipilimumab and PD-1/PDL-1 therapy.

Previous articleHow Idera Pharmaceuticals Inc (NASDAQ:IDRA) Can Fare In Coming Period?
Next articleImmunomedics, Inc. (NASDAQ:IMMU) Gets New Patents For Antibody-Drug Conjugates For Cancer Therapy
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.